Multi-Omics Inflammatory Phenotype for ABPA Recurrence Risk Prediction

NCT07611838 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 300

Last updated 2026-06-01

No results posted yet for this study

Summary

To develop and externally validate a machine learning model for predicting the 1-year risk of relapse in patients with stable ABPA, and to further evaluate its value in risk stratification and clinical decision-making.

Conditions

  • Allergic Bronchopulmonary Aspergillosis (ABPA)
  • Machine Learning
  • Multi-omics
  • Multicenter Study
  • Relapse

Sponsors & Collaborators

  • Qianfoshan Hospital

    lead OTHER

Principal Investigators

  • Qian Qi · Shandong First Medical University

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-01-01
Primary Completion
2028-12-31
Completion
2028-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07611838 on ClinicalTrials.gov